Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Viruses ; 16(1)2023 12 19.
Artigo em Inglês | MEDLINE | ID: mdl-38275940

RESUMO

Human cytomegalovirus (HCMV) is linked to age-related diseases like cardiovascular disease, neurodegenerative conditions, and cancer. It can also cause congenital defects and severe illness in immunocompromised individuals. Accurate HCMV seroprevalence assessment is essential for public health planning and identifying at-risk individuals. This is the first HCMV seroprevalence study conducted in the general Spanish adult population in 30 years. We studied HCMV seroprevalence and HCMV IgG antibody titres in healthy adult donors (HDs) and HCMV-related disease patients from 2010 to 2013 and 2020 to 2023, categorized by sex and age. We compared our data with 1993 and 1999 studies in Spain. The current HCMV seroprevalence among HDs in Spain is 73.48%. In women of childbearing age, HCMV seroprevalence has increased 1.4-fold in the last decade. HCMV-seropositive individuals comprise 89.83% of CVD patients, 69% of SMI patients, and 70.37% of COVID-19 patients. No differences in HCMV seroprevalence or HCMV IgG antibody titres were observed between patients and HDs. A significant reduction in Spanish HCMV seroprevalence among HDs was observed in 1993. However, women of childbearing age have shown an upturn in the last decade that may denote a health risk in newborns and a change in HCMV seroprevalence trends.


Assuntos
Doenças Cardiovasculares , Infecções por Citomegalovirus , Adulto , Humanos , Recém-Nascido , Feminino , Citomegalovirus , Estudos Soroepidemiológicos , Doadores de Tecidos , Anticorpos Antivirais , Imunoglobulina G
2.
Pharmaceutics ; 14(8)2022 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-36015348

RESUMO

In recent years, the use of immune checkpoint inhibitors (ICIs) in combination with approved or experimental vaccines has proven to be a promising approach to improve vaccine immunogenicity and efficacy. This strategy seeks to overcome the immunosuppressive mechanisms associated with the vaccine response, thereby achieving increased immunogenicity and efficacy. Most of the information on the use of ICIs combined with vaccines derives from studies on certain anti-tumor vaccines combined with monoclonal antibodies (mAbs) against either cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death-ligand 1 (PD-L1). However, over the past few years, emerging strategies to use new-generation ICIs as molecular adjuvants are paving the way for future advances in vaccine research. Here, we review the current state and future directions of the use of ICIs in experimental and clinical settings, including mAbs and alternative new approaches using antisense oligonucleotides (ASOs), small non-coding RNAs, aptamers, peptides, and other small molecules for improving vaccine efficacy. The scope of this review mainly includes the use of ICIs in therapeutic antitumor vaccines, although recent research on anti-infective vaccines will also be addressed.

3.
Int Immunopharmacol ; 96: 107761, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-34162139

RESUMO

Since the discovery of lymphocytes with immunosuppressive activity, increasing interest has arisen in their possible influence on the immune response induced by vaccines. Regulatory T cells (Tregs) are essential for maintaining peripheral tolerance, preventing autoimmune diseases, and limiting chronic inflammatory diseases. However, they also limit beneficial immune responses by suppressing anti-infectious and anti-tumor immunity. Mounting evidence suggests that Tregs are involved, at least in part, in the low effectiveness of immunization against various diseases where it has been difficult to obtain protective vaccines. Interestingly, increased activity of Tregs is associated with aging, suggesting a key role for these cells in the lower vaccine effectiveness observed in older people. In this review, we analyze the impact of Tregs on vaccination, with a focus on older adults. Finally, we address an overview of current strategies for Tregs modulation with potential application to improve the effectiveness of future vaccines targeting older populations.


Assuntos
Doenças Autoimunes/terapia , Doença Crônica/terapia , Inflamação/terapia , Linfócitos T Reguladores/fisiologia , Vacinas/imunologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Animais , Doenças Autoimunes/imunologia , Humanos , Fatores Imunológicos/farmacologia , Imunomodulação/fisiologia , Imunossupressores/farmacologia , Inflamação/imunologia , Proteínas de Membrana/metabolismo , Pessoa de Meia-Idade , Vacinação
4.
Biomolecules ; 10(2)2020 02 17.
Artigo em Inglês | MEDLINE | ID: mdl-32079263

RESUMO

: Antisense oligonucleotides (ASOs) are synthetically prepared short single-stranded deoxynucleotide sequences that have been validated as therapeutic agents and as a valuable tool in molecular driving biology. ASOs can block the expression of specific target genes via complementary hybridization to mRNA. Due to their high specificity and well-known mechanism of action, there has been a growing interest in using them for improving vaccine efficacy. Several studies have shown that ASOs can improve the efficacy of vaccines either by inducing antigen modification such as enhanced expression of immunogenic molecules or by targeting certain components of the host immune system to achieve the desired immune response. However, despite their extended use, some problems such as insufficient stability and low cellular delivery have not been sufficiently resolved to achieve effective and safe ASO-based vaccines. In this review, we analyze the molecular bases and the research that has been conducted to demonstrate the potential use of ASOs in vaccines.


Assuntos
Adjuvantes Imunológicos/farmacologia , Imunidade/efeitos dos fármacos , Oligonucleotídeos Antissenso/farmacologia , Adjuvantes Imunológicos/farmacocinética , Animais , Humanos , Oligonucleotídeos Antissenso/imunologia , Oligonucleotídeos Antissenso/farmacocinética , Vacinação , Vacinas/imunologia , Vacinas/farmacocinética , Vacinas/farmacologia
5.
Rev. cuba. hematol. inmunol. hemoter ; 35(2): e954, abr.-jun. 2019.
Artigo em Espanhol | LILACS, CUMED | ID: biblio-1093263

RESUMO

En diciembre de 1943, el Dr. Antonio María Béguez César detalló en el Boletín de la Sociedad Cubana de Pediatría los aspectos clínicos y hematológicos de una rara afección que padecieron tres niños de una familia santiaguera, quienes fallecieron en sus primeros años de vida. No había informes sobre hallazgos similares en la bibliografía médica, por lo cual se consideró la primera descripción de una enfermedad denominada por él como neutropenia crónica maligna familiar con granulaciones atípicas de los leucocitos, que aún hoy suele divulgarse erróneamente como síndrome de Chediak-Higashi y no como síndrome de Béguez-Steinbrinck-Higashi. Esta enfermedad es una inmunodeficiencia primaria causada por mutaciones en el gen regulador de la función lisosomal, capaz de alterar la formación del fagolisosoma en el neutrófilo y determinar la presencia de gránulos secretores gigantes en su interior, asociadas a un predominio de infecciones recurrentes generadas por bacterias piógenas. Aquí se realiza un recuento histórico del descubrimiento de esta entidad y se actualiza su fisiopatología(AU)


On December 1943, Dr. Antonio María Béguez César detailed in the Journal of the Cuban Pediatric Society the clinical and hematologic aspects of a rare disorder suffered by three children from a family in the locality, who expired during the first years of their lives in Santiago de Cuba. At that moment there was no report about similar findings in the medical literature, therefore it is considered the first description of a disease denominated by him as familial malignant chronic neutropenia with atypical granulations of leucocytes, misleadingly revealed as Chediak-Higashi syndrome instead of Béguez-Steinbrinck-Higashi syndrome. This disease consists of a primary immunodeficiency induced by mutations in the regulator gen of the lysosomal function, which is able to alter the formation of phagolysosoma in the neutrophil and determine the presence of giant secretor granules associated with the predominance of recurrent infections provoked by pyogen bacteria. Here, a brief history of it's discovery as well as an updating of it's physiopathology are carried out(AU)


Assuntos
Humanos , Síndrome de Chediak-Higashi/história , Epônimos
6.
Fungal Biol ; 122(12): 1163-1170, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-30449354

RESUMO

Little is known about the differences in the CD4+ T-cell response induced by Sporothrix schenckii and Sporothrix brasiliensis, the most virulent species that cause sporotrichosis. Here, the helper (Th) and regulatory T cells (Tregs) responses were evaluated comparatively in a murine model of sporotrichosis on days 7, 21 and 35 after subcutaneous infection with either S. schenckii or S. brasiliensis conidia. The fungal load was measured at the site of infection, as well as in the liver and spleen. The Th1/Th17/Tregs responses were analyzed in the spleen, while the level of IL-2, IL-4, IL-6, TNF-alpha, IFN-É£, IL-17A and IL-10 cytokines were measured at the local site of infection on 24 h postinfections and in sera on the indicated days. S. brasiliensis caused a longer-lasting infection in the skin and chronic systemic dissemination associated to more severe granulomatous lesions. Similar Th1/Th1-Th17/Tregs responses were induced by both S. brasiliensis and S. schenckii on 7th and 21st d.p.i but on 35 d.p.i a reduction of Th1 and Th1-Th17 cells, associated to higher values of Th17/Tregs cells was observed only in S. brasiliensis-infected mice. In summary, S. brasiliensis caused a more severe disease associated with sustained Th17/Tregs responses than S. schenckii in mice.


Assuntos
Sporothrix/imunologia , Sporothrix/patogenicidade , Esporotricose/patologia , Linfócitos T Reguladores/imunologia , Células Th17/imunologia , Animais , Contagem de Colônia Microbiana , Citocinas/análise , Modelos Animais de Doenças , Granuloma/patologia , Fígado/microbiologia , Camundongos , Pele/patologia , Baço/microbiologia , Células Th1/imunologia , Fatores de Tempo
7.
Vaccine ; 35(34): 4430-4436, 2017 08 03.
Artigo em Inglês | MEDLINE | ID: mdl-28687406

RESUMO

Sporotrichosis is an important zoonosis in Brazil and the most frequent subcutaneous mycosis in Latin America, caused by different Sporothrix species. Currently, there is no effective vaccine available to prevent this disease. In this study, the efficacy and toxicity of the adjuvant Montanide™ Pet Gel A (PGA) formulated with S. schenckii cell wall proteins (ssCWP) was evaluated and compared with that of aluminum hydroxide (AH). Balb/c mice received two subcutaneous doses (1st and 14th days) of either the unadjuvanted or adjuvanted vaccine candidates. On the 21st day, anti-ssCWP antibody levels (ELISA), the phagocytic index, as well as the ex vivo release of IFN-γ, IL-4, and IL-17 by splenocytes and IL-12 by peritoneal macrophages were assessed. Cytotoxicity of the vaccine formulations was evaluated in vitro and by histopathological analysis of the inoculation site. Both adjuvanted vaccine formulations increased anti-ssCWP IgG, IgG1, IgG2a, and IgG3 levels, although IgG2a levels were higher in response to PGA+CWP100, probably contributing to the increase in S. schenckii yeast phagocytosis by macrophages in the opsonophagocytosis assay when using serum from PGA+CWP100-immunized mice. Immunization with AH+CWP100 led to a mixed Th1/Th2/Th17 ex vivo cytokine release profile, while PGA+CWP100 stimulated a preferential Th1/Th2 profile. Moreover, PGA+CWP100 was less cytotoxic in vitro, caused less local toxicity and led to a similar reduction in fungal load in the liver and spleen of S. schenckii- or S. brasiliensis-challenged mice as compared with AH+CWP100. These results suggest that PGA may be an effective and safe adjuvant for a future sporotrichosis vaccine.


Assuntos
Adjuvantes Imunológicos , Hidróxido de Alumínio/imunologia , Vacinas Fúngicas/efeitos adversos , Vacinas Fúngicas/imunologia , Sporothrix/imunologia , Esporotricose/prevenção & controle , Adjuvantes Imunológicos/toxicidade , Hidróxido de Alumínio/toxicidade , Animais , Anticorpos Antifúngicos/biossíntese , Anticorpos Antifúngicos/sangue , Anticorpos Antifúngicos/imunologia , Brasil , Vacinas Fúngicas/administração & dosagem , Vacinas Fúngicas/química , Imunidade Celular , Imunogenicidade da Vacina , Interleucina-17/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Fagocitose , Esporotricose/imunologia , Equilíbrio Th1-Th2 , Vacinação
8.
Microb Pathog ; 110: 78-84, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-28645771

RESUMO

The available information about the role of Dectin-1 in sporotrichosis is scarce. Hence, we aimed to assess Dectin-1 expression by macrophages and the activation of some related antifungal mechanisms during the Sporothrix schenckii sensu stricto infection as a first attempt to elucidate the role of this receptor in sporotrichosis. Balb/c mice were intraperitoneally infected with S. schenckii sensu stricto yeast ATCC 16345 and euthanized on days 5, 10 and 15 post-infection, when the following parameters were evaluated: fungal burden in spleen, Dectin-1 expression and nitric oxide (NO) production by peritoneal macrophages, as well as IL-1ß, TNF-α and IL-10 ex vivo secretion by these same cells. Peritoneal macrophages were ex vivo challenged with either the alkali-insoluble fraction (F1) extracted from the S. schenckii cell wall, a commercially available purified ß-1,3-glucan or whole heat-killed S. schenckii yeasts (HKss). Additionally, a Dectin-1 antibody-mediated blockade assay was performed on day 10 post-infection to assess the participation of this receptor in cytokine secretion. Our results showed that Dectin-1 expression by peritoneal macrophages was augmented on days 10 and 15 post-infection alongside elevated NO production and ex vivo secretion of IL-10, TNF-α and IL-1ß. The antibody-mediated blockade of Dectin-1 inhibited cytokine production in both infected and non-infected mice, mainly after ß-1,3-glucan stimulation. Our results suggest a role for Dectin-1 in triggering the immune response during S. schenckii infection.


Assuntos
Antifúngicos/farmacologia , Lectinas Tipo C/metabolismo , Macrófagos/metabolismo , Sporothrix/efeitos dos fármacos , Sporothrix/patogenicidade , Esporotricose/imunologia , Animais , Citocinas/metabolismo , Modelos Animais de Doenças , Interleucina-10/metabolismo , Interleucina-1beta/metabolismo , Lectinas Tipo C/imunologia , Macrófagos/imunologia , Macrófagos Peritoneais/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Óxido Nítrico/metabolismo , Baço/microbiologia , Esporotricose/microbiologia , Fator de Necrose Tumoral alfa/metabolismo
9.
Rev. peru. med. exp. salud publica ; 30(3): 441-445, jul.-sep. 2013. ilus, graf, tab
Artigo em Espanhol | LILACS, LIPECS | ID: lil-688044

RESUMO

El objetivo del estudio fue determinar los epítopes T de cuatro de las proteínas antigénicas más frecuentes de la membrana externa de Neisseria meningitidis B e identificar los sitios más relevantes donde existe mimetismo molecular para estos epítopes en seres humanos. Para ello se realizó un estudio in silico (estudios que usan herramientas bioinformáticas) usando las bases de datos SWISS-PROT/TrEMBL SYFPEITHI y FASTA, las cuales se emplearon para la determinación de las secuencias proteicas, la predicción de los epítopes T CD4 y CD8, y la determinación del mimetismo molecular en humanos, respectivamente. Se encontró similitud molecular en varias proteínas humanas presentes en diferentes órganos y tejidos, entre ellos: hígado, piel y epitelios, cerebro, sistema linfático y testículos, destacando las encontradas en estos últimos, ya que ellas mostraron la frecuencia más alta de secuencias miméticas. Este hallazgo ayuda a comprender el éxito de N. meningitidis B para colonizar tejidos humanos, el fracaso de ciertas vacunas contra esta bacteria e incluso ayuda a explicar posibles reacciones autoimmunes asociadas a la infección o vacunación.


The objective of the study was to determine the T-cell epitopes of four of the most frequent antigenic proteins of the outer membrane of Neisseria meningitidis B, and to identify the most relevant sites for molecular mimicry with T-cell epitopes in humans. In order to do so, an in silico study -a type of study that uses bioinformatic tools- was carried out using SWISS-PROT/TrEMBL, SYFPEITHI and FASTA databases, which helped to determine the protein sequences, CD4 and CD8 T-cell epitope prediction, as well as the molecular mimicry with humans, respectively. Molecular similarity was found in several human proteins present in different organs and tissues such as: liver, skin and epithelial tissues, brain, lymphatic system and testicles. Of these, those found in testicles were more similar, showing the highest frequency of mimetic sequences. This finding shed light on the success of N. meningitidis B to colonize human tissues and the failure of certain vaccines against this bacterium, and it even helps to explain possible autoimmune reactions associated with the infection or vaccination.


Assuntos
Humanos , Antígenos de Bactérias/imunologia , Simulação por Computador , Epitopos de Linfócito T/imunologia , Mimetismo Molecular , Neisseria meningitidis Sorogrupo B/imunologia , Proteoma
10.
Medisan ; 16(8): 1284-1294, ago. 2012.
Artigo em Espanhol | LILACS | ID: lil-647020

RESUMO

En este estudio se evaluó el efecto del adyuvante Finlay cocleato 1 (AFCo1), aplicado 4 veces por vía intranasal en 2 niveles de dosis (50 µg y 100 µg) sobre la concentración plasmática de teofilina, administrada a las 24 horas de la última aplicación (5 mg/kg, por vía intraperitoneal) en ratas Sprague-Dawley. Se empleó como control positivo de inflamación la aplicación de 2 dosis por vía subcutánea de adyuvante completo de Freund (ACF). Las ratas que recibieron AFCo1 no mostraron cambios significativos en la concentración sérica de teofilina; mientras que las tratadas con ACF desarrollaron inflamación local asociadas a signos de toxicidad a la teofilina y elevación de las cifras de inmunoglobulina G específica, de las concentraciones plasmáticas y el tiempo de vida media de teofilina en suero, en comparación con los grupos restantes. Estos resultados indican que la inmunoestimulación inducida por AFCo1 intranasal no incrementa los parámetros farmacocinéticos ni la toxicidad de la teofilina en el modelo empleado.


The effect of the adjuvant Finlay cochleate1 (AFCo1), applied intranasally 4 times in 2 dose levels (50 µg and 100 µg) on plasma concentration of theophylline administered 24 hours after the last application (5 mg/kg intraperitoneally) in Sprague-Dawley rats was evaluated in this study. Application subcutaneously of 2 doses of Freund's complete adjuvant (FCA) was used as positive control of inflammation. Rats receiving AFCo1 had no significant changes in serum theophylline concentration, while those treated with FCA developed local inflammation associated with signs of theophylline toxicity and increased specific G immunoglobulin, plasma concentrations and serum theophylline half-life as compared with the remaining groups. These results show that intranasal AFCo1-induced immunostimulation does not increase pharmacokinetic parameters and theophylline toxicity in the model used.

11.
Rev. peru. med. exp. salud publica ; 29(2): 265-271, abr.-jun. 2012. ilus, tab
Artigo em Espanhol | LILACS, LIPECS | ID: lil-644013

RESUMO

La posible asociación entre vacunas y enfermedades autoinmunes es un tema controversial. Existen elementos a favor de esta relación basados en modelos teóricos, ensayos de laboratorio y varios casos clínicos publicados. En cambio, los estudios epidemiológicos no han confirmado esta asociación y, de ellos, puede inferirse que las vacunas no constituyen una causa demostrada de enfermedades autoinmunes. En este trabajo se analizan las evidencias a favor y en contra de esta controversial asociación, además, se aborda un nuevo síndrome asociado con la administración continuada de adyuvantes vacunales. Se concluye que debido al gran impacto en beneficio de la salud logrado con las vacunas, es necesario continuar desarrollando esta tecnología, pero también se debe seguir perfeccionando los diseños de las nuevas formulaciones y profundizando estudios básicos, preclínicos, ensayos clínicos y farmacovigilancia de los nuevos candidatos vacunales para establecer el riesgo real de desarrollo de un evento autoinmune posvacunación.


The occurrence and significance of autoimmune manifestations after administration of vaccines remain controversial. Evidence for immunization triggered autoimmunity come from several sources including theoretical models, animal studies, single and multiple case reports. In contrast, several epidemiological studies don’t report this association, which is reassuring and at least indicates that vaccines are not a major cause of autoimmune diseases. We analyzed current scientific data concluded that vaccines bring a positive impact on public health, so it is necessary to continue developing this technology. Evaluation methods should be improved to avoid or anticipate the possible autoimmune side effects that can be presented.


Assuntos
Humanos , Doenças Autoimunes/etiologia , Vacinas/efeitos adversos , Vacinas/imunologia
12.
Bol. latinoam. Caribe plantas med. aromát ; 10(3): 256-264, mayo 2011. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-687015

RESUMO

A preclinical study was carried out to determinate the protective properties of Petiveria alliacea Linn on 5-Fluoruracilo (5-FU)-immunosuppressed animals, a cytostatic drug often used in cancer treatment. Were use five groups of female Balb/c mice (5 mice/group).Two groups were treated with 400 and 1200 mg/kg of P. alliacea leaves and stems powder respectively, and a third group was treated with carboxymethyl cellulose as vehicle. Two additional control groups were set up: a 5-FU treated group, as immunosuppression control, and a NaCl solution (0.9 percent treated group. Animals were treated daily for five days and then a unique dose of 150 mg/kg of 5-FU was administered and the treatment continued for another four days. At termination blood and tissue samples were collected for leukocyte total count, analysis of bone marrow cellularity, thymus weight and total IgG antibody forming cells. Our results show that the group treated with the highest dose of P. alliacea, was less affected by 5-FU-induced immunosupresion compared with the other treated groups. The results derived from this study suggest that P. alliacea, a medicinal plant product, could be used in patients under antineoplasic regimens to avoid the deleterious adverse effects of the immunosuppressive drugs.


Se realizó un estudio preclínico para la determinación de las propiedades protectoras de la planta Petiveria alliacea Linn sobre la inmunosupresión inducida por la droga citostática 5- Fluoruracilo (5-FU), la cual se utiliza muy frecuentemente en la terapia contra el cáncer. Se utilizaron cinco grupos de ratones hembras Balb/c (5 ratones por grupo) que incluyeron dos grupos de tratamiento con dos niveles de dosis del polvo de las hojas y tallos de la planta: 400 y 1200 mg/kg, así como grupos controles con solución de NACl y con el vehículo (solución de carboximetil celulosa) por vía oral, aplicados durante 5 días, luego una administración única de 150 mg/kg de 5-FU y la continuación del tratamiento en los restantes 5 días. En las variables: conteo global y diferencial de leucocitos, celularidad de la médula ósea, peso del timo y Células Formadoras de Anticuerpos (CFA) IgG totales, se pudo observar que el grupo de mayor dosis de P. alliacea tuvo una menor afectación por la inmunosupresión inducida por 5-FU, en comparación con el resto de los grupos tratados. Estos resultados apoyan el uso de formulaciones de esta planta en pacientes que reciben tratamientos antineoplásicos para la protección contra la inmunosupresión.


Assuntos
Animais , Feminino , Camundongos , Adjuvantes Imunológicos/farmacologia , Folhas de Planta/química , Phytolaccaceae/química , Adjuvantes Imunológicos/administração & dosagem , ELISPOT , Terapia de Imunossupressão , Camundongos Endogâmicos BALB C , Tamanho do Órgão , Caules de Planta/química
13.
Medisan ; 15(1): 50-57, ene. 2011.
Artigo em Espanhol | LILACS | ID: lil-585323

RESUMO

Se realizó un estudio descriptivo y transversal de 32 familias con casos secundarios de lepra (entre los cuales predominaron los pacientes menores de 15 años, como evidencia de la transmisión activa de la enfermedad) y contactos de primer orden, pertenecientes al área de salud Frank País García de Santiago de Cuba, desde enero del 2007 hasta marzo del 2008, a fin de caracterizarles según elementos inmunológicos y epidemiológicos. El número de eosinófilos puede ser utilizado como marcador para pronosticar la evolución de los pacientes y contactos; asimismo, la neutrofilia y la eosinofilia por una parte y la leucopenia, la linfopenia y las alteraciones en la calidad de los clones linfocitarios T, por la otra, pudieran considerarse en función de marcadores de efecto: los primeros como indicativos de respuesta ante el Mycobacterium leprae y los segundos como expresión del daño inmunológico existente


A descriptive and cross-sectional study of 32 families with secondary cases of leprosy was carried out (among them prevailed the patients younger than 15 years, as evidence of the active transmission of the disease) and first contacts belonging to Frank País García health area in Santiago de Cuba, from January, 2007 to March, 2008, to characterize them according to the immunological and epidemiological elements. The number of eosinophils may be used as a marker to predict the clinical course of the patients and contacts; the neutrophilia, the eosinophilia on the one hand and the leukopenia, lymphocytopenia and disorders in the quality of the lymphocitary clones T, on the other hand, could be considered as effect markers: the former as indicative of response before the Mycobacterium leprae and the latter as expression of the existing immunological damage


Assuntos
Humanos , Masculino , Feminino , Hanseníase , Hanseníase/epidemiologia , Hanseníase/imunologia , Programas Nacionais de Saúde , Fatores de Risco , Estudos Transversais , Epidemiologia Descritiva
14.
Bol. latinoam. Caribe plantas med. aromát ; 9(6): 457-464, nov. 2010. graf, tab
Artigo em Inglês | LILACS | ID: lil-644984

RESUMO

Patients receiving chemotherapy treatment in Santiago de Cuba traditionally use water extracts from Trichilia hirta roots. The study aim was to evaluate the immunorestorative and cytotoxic activity of water extracts from Trichilia hirta root. Administration of root water extract increased the total and differential leukocyte counts in inmunosupressed Balb/c mice. Thymus weight recovered significantly as well as bone marrow cellularity. Moreover, water extract (125 ug/mL) showed selective cytotoxicity against cancer cells T-47D and SK-mel-3 in comparison with non-cancer cells (Vero). The results indicate that Trichilia hirta has significant immunorestorative effects in vivo and selective cytotoxicity in vitro. Therefore, it might be a promising alternative for cancer therapy.


Pacientes bajo tratamiento quimioterapéutico tradicionalmente usan extractos acuosos de raíz de Trichilia hirta en Santiago de Cuba. El objetivo de este estudio fue evaluar la actividad inmunorestauradora y citotóxica de extractos acuosos de raíz de Trichilia hirta. La administración del extracto acuoso de raíz incrementó los conteos globales y diferenciales de leucocitos en ratones inmunodeprimidos. El peso del timo, así como, la celularidad de la médula ósea se recuperaron significativamente. Además, el extracto acuoso (125 ug/mL) mostró citotoxicidad selectiva contra las células tumorales T-47D y SK-mel-3 en comparación con la línea no tumoral (Vero). Los resultados indican que Trichilia hirta posee significativos efectos inmunorestauradores in vivo y citotoxicidad selectiva, por lo cual podría ser una promisoria alternativa para la terapia del cáncer.


Assuntos
Animais , Ratos , Extratos Vegetais/farmacologia , Imunidade , Meliaceae/química , Proliferação de Células , Raízes de Plantas , Hospedeiro Imunocomprometido , Camundongos Endogâmicos BALB C , Polissacarídeos , Ensaio Tumoral de Célula-Tronco
15.
Medisan ; 8(3)jul.-sept. 2004.
Artigo em Espanhol | LILACS | ID: lil-463234

RESUMO

Se presenta una amplia información general sobre la planta medicinal de uso tradicional anamú (Petiveria alliacea L.), muy abundante en el país. Adicionalmente se exponen los principales resultados etnomédicos, preclínicos, farmacológicos y toxicológicos, cuya evaluación por la autoridad regulatoria cubana de medicamentos condujo a la aprobación del registro de la tableta de Anamú en la categoría de medicamento herbario inmunoestimulante


Assuntos
Medicina Herbária , Medicina Tradicional , Extratos Vegetais , Plantas Medicinais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA